Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases

A Randomized, Controlled Trial of Target Therapy Plus Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01677728

Enrollment

Registered

2012-09-03

Start date

2007-01-31

Completion date

2014-12-31

Last updated

2012-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Liver Tumor

Keywords

colorectal liver metastases, chemotherapy, cetuximab, bevacizumab

Brief summary

The aim of this study is to explore whether target therapy in combination with chemotherapy as treatment could improve survival or tumor response in patients undergoing Synchronic Hepatectomy for Colorectal Liver Metastases.

Detailed description

In patients with colorectal cancer (CRC), the liver is the most common site of hematogenous metastases. Approximately half of patients develop hepatic metastases during the course of the disease, and hepatic metastases are responsible for death in at least two thirds of CRC patients. Over the past decade, due to the introduction of irinotecan-based or oxaliplatin-based combination chemotherapy, the median survival among patients with colorectal liver metastases (CLM) has increased from 6 \ 8 months to more than 20 months5.In recent years, target therapy has rapidly gained attention for the treatment of CLM and is under active investigation. Although numerous publications have reported the efficacy of target therapy in combination treatment for CLM patients, most of these studies focused solely on those patients without undergoing resection of liver metastases. In contrast, little work has concentrated on exploring the effection of target therapy for CLM patients undergoing Synchronic Hepatectomy.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* age between 18 - 75 years old * Performance status (ECOG) 0\ 1 * colorectal adenocarcinoma pathologically * without any chemotherapy or radiotherapy * liver metastases undergoing radical resection * colorectal cancer undergoing radical resection * no other metastases * suitable for chemotherapy * agreed by patients

Exclusion criteria

* age below 18 years old or greater than 75 years old * haven't pathological diagnosis of colorectal adenocarcinoma with liver metastase * with any chemotherapy or radiotherapy * with other metastasis * unresectable colorectal cancer or liver metastases * unsuitable for chemotherapy or target therapy * not agreed by patients

Countries

China

Contacts

Primary ContactXu Jianmin, MD

xujmin@yahoo.com.cn+86-13501984869

Outcome results